ArticleNutrition & metabolism2026
Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic disease, but it remains unclear whether it is related to dietary folate. This research sought to investigate the association between dietary folate and MASLD.
methodsThis cohort study utilized the UK Biobank (UKB) database (N = 58,047). Dietary folate intake was assessed using an online dietary questionnaire, and MASLD was ascertained through International Classification of Diseases, Tenth Revision (ICD-10). Cox proportional hazard regression, mediation analysis and restricted cubic splines (RCS) were employed to investigate the association and dose-response relationship between dietary and MASLD. The stability of findings was verified by stratified analyses and sensitivity analyses.
resultsDietary folate intake was observed to be negatively associated with MASLD in cohort studies. During a median follow-up of 12.18 years, 691 cases of MASLD occurred. The risk of MASLD decreased by 24% (HR = 0.76, 95% CI: 0.59-0.97) among the participants in the highest dietary folate intake relative to lowest quartile. The protective effect was more pronounced in participants aged < 60 years (HR = 0.63, 95% CI: 0.45-0.89), male (HR = 0.63, 95% CI: 0.44-0.89), and obese participants (HR = 0.68, 95% CI: 0.48-0.95). The research results remained robust in the sensitivity analyses that excluded participants with ≤ 2 years of follow-up time, extremely folate intake, and other conditions. C-reactive protein (CRP) explained 6.56% of the association between dietary folate and MASLD. The dietary folate intake had an L-shaped relationship with the risk of MASLD (P for nonlinearity = 0.003).
conclusionsModerate folate intake (approximately 300 µg) may reduce the risk of MASLD, suggesting that promoting folate-rich diets may be a viable and cost-effective strategy for MASLD prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.